Rethinking the criteria for fibromyalgia in 2019: the ABC indicators. by Stewart, Julian A. et al.
OR I G I N A L R E S E A R C H
Rethinking the criteria for ﬁbromyalgia in 2019:
the ABC indicators
This article was published in the following Dove Press journal:
Journal of Pain Research
Julian A Stewart 1
Simone Mailler-Burch1
Darius Müller1
Martina Studer1
Roland von Känel 2,3
Martin grosse Holtforth 1,4
Kyrill Schwegler1
Niklaus Egloff 1,2
1Department of Neurology, Bern
University Hospital, University of Bern,
Bern, Switzerland; 2Department of
Clinical Research, Bern University
Hospital, University of Bern, Bern,
Switzerland; 3Department of
Consultation-Liaison Psychiatry and
Psychosomatic Medicine, University
Hospital Zurich, University of Zurich,
Zurich, Switzerland; 4Department of
Psychology, University of Bern, Bern,
Switzerland
Purpose: Diagnostic criteria for ﬁbromyalgia have been subject to debate and controversy
for many years. The preliminary diagnostic criteria introduced in 2010 and 2011 have been
criticized for different reasons, including questionable diagnostic speciﬁcity and a lack of an
etiopathogenetic foundation. The “ABC indicators” presented in this study reﬂect a further
development of the 2011 criteria and refer to (A) algesia, (B) bilateral, axial-symmetric pain
distribution, and (C) chronic distress.
Patients and methods: We compared the diagnostic performance of the ABC indicators
with that of the 2011 criteria by analyzing the data of 409 inpatients with chronic functional
pain divided into two subgroups of pain patients: Those with whole-body pain and those with
pain not involving the whole body. Under the premise that FM phenotypically represents a
whole-body pain disorder, sensitivity, speciﬁcity, correct classiﬁcation and diagnostic odds
ratios were calculated.
Results: The 2011 criteria demonstrated a speciﬁcity of 68.1%, a sensitivity of 75.5%, a
correct classiﬁcation of 71.0% and a diagnostic odds ratio of 6.56 (CI: 4.17–10.31). The
ABC indicators achieved a speciﬁcity of 88.3%, a sensitivity of 62.3%, a correct classiﬁca-
tion of 78.6%, and a diagnostic odds ratio of 12.47 (CI: 7.30–21.28).
Conclusion: The ABC ﬁbromyalgia indicators demonstrated better speciﬁcity, lower sensi-
tivity, and better overall diagnostic effectiveness than the original 2011 criteria.
Keywords: chronic pain, diagnostic criteria, widespread pain, hyperalgesia, psychological
distress, Complex Generalized Pain Syndrome (CGPS)
Introduction
The ongoing problem with diagnosing ﬁbromyalgia by the
ACR criteria
Since their inception in 1990, criteria for the diagnosis of the ﬁbromyalgia syn-
drome (FM) have been discussed controversially.1–4 Recent literature has high-
lighted current uncertainty and skepticism of the diagnosis of FM in the general
medical community.5,6 Aiming to overcome previous shortcomings, experts pro-
posed new diagnostic criteria for FM to the American College of Rheumatology
(ACR) in 2010, with a revised version subsequently published in 2011.7,8 Both the
2010 and 2011 criteria are based on satisfying one of two numerical cut-off
combinations of the Widespread Pain Index (WPI) and the Symptom Severity
Score (SSS). The WPI is an inventory of the occurrence of pain in 19 deﬁned
body locations. The SSS contains the four items fatigue, non-restorative sleep,
cognitive symptoms and an item comprising a multiplicity of other concomitant
symptoms.7,8
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Even though the 2010/2011 criteria are easy-to-admin-
ister, uncertainty remained regarding its clinical validity.9
Concerns raised were a) the lack of any pathophysiological
disease concept underlying the criteria; b) exclusive reli-
ance on self-reported symptoms; c) inconclusive recom-
mendations for their use in overlapping rheumatological
diseases, and d) insufﬁcient diagnostic speciﬁcity and dif-
ferentiation from localized functional pain syndromes.10
In a previous study, the limitations of the ACR criteria
2010/2011 were examined in relation to other functional
pain syndromes.10 By realizing the latter diagnostic deﬁcit
of the ACR criteria 2010/2011, Wolfe and colleagues
aimed to increase speciﬁcity by (re-)deﬁning FM as a
generalized pain syndrome in 2016.11,12 Additively to the
SSS and WPI scores, they reintroduced a widespread pain
criterion (whole-body pain with pain in at least 4 of 5
deﬁned body regions), while retaining the arguably redun-
dant WPI-limit, which overlaps with the reintroduced
widespread pain criterion. To summarize, in 2016 FM
still appears as a “non-clinical diagnosis”, emerged out
of 3 checklists (with many redundancies) and without
any visible underlying pathophysiological concept.
Therefore, we fear that the acceptance and communicabil-
ity of FM criteria remain limited.5,6 We believe that
despite the ACR’s decision in 2015 “to cease funding
and endorsing research on further diagnostic criteria”, the
FM diagnosis still needs optimization.13
Alternatives in diagnosing FM are needed
Analogous to the Complex Regional Pain Syndromes
(CRPS), we support the paradigm which deﬁnes FM as a
Complex Generalized Pain Syndrome (CGPS). Neurogenic
inﬂammatory modulation processes have been demonstrated
to play a role in both CRPS and FM.14 However, for both
pain disorders there is no generally accepted neurochemical
surrogate-marker to identify the disorders (yet).
Subsequently, the diagnosis must further be made phenoty-
pically. Analogous to the “Budapest Criteria” for CRPS, the
“ABC Indicators” presented in this study introduce a method
to diagnose FM phenotypically. By retaining the SSS, they
reﬂect a possible further development of the 2011 ACR
criteria.
However, before proposing new ways to optimize FM
diagnosis, the function of the medical-diagnostic process
of FM criteria must undoubtedly be clariﬁed: As experts
share the opinion that FM may occur alongside, for exam-
ple, rheumatological diseases, FM may neither represent
an exclusion diagnosis, nor a residual category within
rheumatological diseases (Figure 1).12–14
Based on the above-mentioned possibility of a comor-
bid rheumatological disorder, peripheral biomorphologic
pain correlates must be identiﬁed or ruled out in clinical
practice, as is the case with any other complex pain
syndrome.
Additionally and independent of this ﬁrst step, patients
should be tested speciﬁcally for FM symptoms. In absence
of a simple diagnostic surrogate-marker-test for FM,
patients should be tested for positive clinical characteris-
tics of FM. These clinical indicators should be in line with
the current medical understanding of the syndrome. The
combination of the indicators should capture the clinical
phenotype of FM as accurately as possible and correctly
identify it within the spectrum of other pain syndromes.
ABC indicators refer to the pathophysiology
The current understanding of FM focusses primarily on
altered neuronal perception resulting in generalized heigh-
tened sensitivity to various stimuli due to changes in the
Functional pain syndromes
Comorbidities
Rheumatological diseases
Fibromyalgia-syndrome
(Including other diseases with pain, not
explainable by lesions or inflammations)
(Including other diseases with wide-
spread pain, explainable by lesions
or inflammations)
Indicator A: Algesia
Indicator C: Chronic distress
Indicator B: Bilateral
axially-symmetrical pain
Figure 1 The ﬁbromyalgia syndrome and the ABC indicators within the context of functional pain syndromes and rheumatological diseases.
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central nervous, neuroendocrine and autonomic nervous
systems.13,15–25 Several neurogenic neuroinﬂammatory
processes may contribute to the Symptoms of FM.14
Some studies also describe additive peripheral nerve dys-
function in some FM subgroups.26 Based on these essen-
tial mechanisms of generalized hypersensitivity, the
enhanced proprioception of musculoskeletal segments
typically occurs in an axial-symmetric (bilateral) pain dis-
tribution pattern, similar to muscle pain experienced with
inﬂuenza (see Figure 2).27
Altered stress-related processing likely accounts for the
high prevalence of comorbid vegetative, affective and cog-
nitive (psychological) symptoms in FM.25 Recent research
demonstrated higher levels of stress to be associated with
reduced pressure pain-thresholds.28 In animal models of
FM, rodents repeatedly exposed to stress exhibited chan-
ging signal pathways in central and peripheral pain
processing, resulting in hyperalgesia.29–33 Accordingly,
the term stress-induced hyperalgesia has been coined for
this crucial pathophysiological link between chronic stress-
exposure and generalized pain sensitization in FM.34,35
Based on these pathogenetic mechanisms, the “ABC
indicators of FM” circumscribe the following key features
of FM:
Indicator A: Algesia (hyperalgesia operationalized
through pain pressure algometry),
Indicator B: Bilateral, multilocular, axial-symmetric
pain distribution pattern (operationalized through pain
drawings or clinical examination), and
Indicator C: Chronic distress symptoms (operationa-
lized through standardized questionnaires or SSS 2011).
In detail, the clinical indicators (A, B, and C) serve slightly
different steps in the diagnostic process: (See Figure1). While
indicator A (algesia) and indicator C (chronic distress) are also
Figure 2 Pain drawing example of bilateral axial-symmetric pain distribution.
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common positive characteristics in other functional pain syn-
dromes (eg irritable bowel syndrome), the additional need for
indicator B (bilateral, axial-symmetric pain) aids the selection
of FM as generalized pain disorder within this spectrum of
functional pain syndromes.36 Due to ubiquitously lowered
thresholds in proprioception, FM consequently appears pre-
dominantly as “whole-body-pain”, identiﬁable with its typical
multilocular axial-symmetric bilateral pain-pattern.
Methodologically, the concept of the ABC indicators is
consistent with recent IMMPACT recommendations expli-
citly advocating use of various psychosocial and psycho-
physical (quantitative sensory testing) instruments for
phenotyping pain disorders.37
Aims of the present study
To evaluate the diagnostic application of the ABC indica-
tors within the spectrum of functional pain syndromes, we
compared the diagnostic parameters of the FM 2011 cri-
teria with the ABC indicators. Since no gold-standard
exists to validate different FM-criteria concepts, indirect
test methods are implemented: Based on the pathophysio-
logical aspect of generalized hyperalgesia, we predict FM
to be a “complex generalized pain syndrome” within the
spectrum of functional pain syndromes. This paradigm of
generalized pain is congruent with the recent re-adapta-
tions of Wolfe and colleagues in 2016, reintroducing a
widespread pain criterion.12,13
More speciﬁcally, we aimed to compare ACR criteria
2011 and the ABC indicators in their capacity to select
whole-body-pain in a cohort of over 400 patients with
functional pain syndromes. We deﬁne whole-body-pain
as pain in at least 4 of 6 deﬁned body areas (extremities,
trunk, and head). We consequently deﬁne “false-positive”
cases as fulﬁlling the FM criteria, despite not having
whole-body-pain (eg, a patient fulﬁlling the 2011 FM
criteria while only reporting pain in the left arm and
right leg would be considered a false-positive case).
In consequence to these premises we expect (I) signiﬁ-
cantly higher values of the clinical indicators (A, B & C)
in the whole-body-pain group compared to the non-whole-
body-pain group as well as healthy controls. Since bilat-
eral, axial-symmetric pain distribution (indicator B) is
viewed as an explicit key criterion for generalized hyper-
algesia, we expect (II) indicator B to be predominantly
observed in the whole-body-pain group, in which we
assume FM to be represented. Furthermore, as FM is
considered a stress-related syndrome, we hypothesize par-
ticularly high levels of distress in patients with the whole-
body-pain disorders (III). With respect to the ACR criteria
2011 we expect signiﬁcant correlations between the SSS
and other measures of psychological distress (IV).
The aims of the present study are summarized as
follows:
● To examine the ABC indicators when comparing the
whole-body-pain group to the non-whole-body-pain
group
● To examine the rate of bilateral, axial-symmetric pain
distributions in the whole-body pain group compared
to the non-whole-body-pain group
● To examine the levels of psychological distress in the
whole-body-pain group compared to the non-whole-
body-pain group
● To examine the association between the SSS and the
measures of psychological distress
Materials and methods
Participants
Data were collected from 409 consecutively admitted
inpatients with different chronic functional pain syn-
dromes at admission to a multimodal interdisciplinary
treatment program in a tertiary university pain clinic as
part of a standard clinical assessment. Patients with acute
psychosis or severe addiction were excluded from partici-
pation in study. Furthermore, patients with primarily neu-
rological or primarily inﬂammatory diseases were
excluded from participation in study. Patients were over
18 years of age, suffered from ≥1 functional pain syn-
dromes. All patients provided written informed consent
for the reuse of their health data for research purposes.
The study performed in compliance with the Declaration
of Helsinki and was approved by the local institutional
review board (Kantonale Ethikkomission Bern, 2018–
00467). All available information from hospital charts,
previous clinical assessments, as well as radiological and
serological data were thoroughly reviewed at admission,
and further assessments were performed as needed in order
to specify the pain syndrome origin.
All patients were examined by internal medicine resi-
dents and supervised by board-certiﬁed internists and psy-
chiatrists trained in pain medicine. The physicians
conducted a structured interview about the patient’s med-
ical history including information on various pain charac-
teristics (intensity, type and dynamics of pain, factors
modulating pain intensity, pain localization, concomitant
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symptoms and effects of analgesics) and rated the
Symptom Severity Score (SSS). A second, semi-structured
part of the interview focused on demographic data and
adverse life events. Psychiatric comorbidities were identi-
ﬁed with diagnostic instruments and further validated
through observation over the course of inpatient treatment.
Diagnoses were classiﬁed according to ICD-10 criteria.38
Measures
The German version of the Hospital Anxiety and
Depression Scale (HADS) was used for the assessment
of anxiety and depression symptoms experienced
admission.39 The HADS consists of two scales with
seven items each ranging from 0 to 21. Both scores have
a cut-off at ≥8 points for clinically relevant symptoms.40
The sum of the anxiety and depression scores can be used
to measure “total distress” with a cut-off ≥15.41 The
German version of the Brief Symptom Inventory (BSI),
containing 53 items, was used to self-rate psychopatholo-
gical symptoms and emotional distress subscales.42
Cronbach’s alpha yielded good to excellent internal con-
sistency for all scales used in the present study (BSI total:
0.96; BSI anxiety: 0.81; BSI depression: 0.84; HADS
total: 0.87; HADS anxiety: 0.80; HADS depression: 0.82).
A standardized and validated pressure-pain provocation
test was applied To assess hyperalgesia.43 This method
represents a cost-saving and reliable alternative to electro-
nic measurement instruments.44 Since this test is not subject
to a patent, it can be implemented and easily reproduced all
over the world.43,44 The method is easy-to-administer and
has been implemented in several studies.10,27,36,43–45,56
Selected by means of spring balances, the pegs used for
pain provocation are set with an exact clamping force of
10N, at an extension of 5 mm (Type Algopeg, size
78×10 mm, polypropylene and nickel). The test is adminis-
tered at both right and left earlobes (without touching ear
cartilage) and middle ﬁngers (without touching the nail-
fold). After a duration of 10 seconds the peg was removed
and patients were asked to report the intensity of the pro-
voked pain on a numerical rating scale (NRS) of 0–10
(0= “no pain”, 10= “most intense pain imaginable”). After
computing the average value of the right and left middle
ﬁngers and ear lobes, we obtained the following variables:
Pain level middle ﬁnger (NRS 0–10), pain level earlobe
(NRS 0–10). “Hyperalgesia” was deﬁned clinically as a
reported pain level of ≥3 at the middle ﬁnger or a pain
level of ≥8 at the earlobe. This deﬁnition of hyperalgesia
is based on reference data from 676 healthy subjects. For
healthy central European subjects, the mean pain sensitivity
at the middle ﬁnger is 1.6 (SD 1.5) and the mean pain
sensitivity at the earlobe is 5.6 (SD 2.3) (www.algopeg.ch).
Each patient was carefully instructed to provide a
detailed pain drawing (PD) of his/her pain sensations. PD
is an important and easy-to-administer tool for obtaining
additional non-verbal information about an individual’s
pain distribution pattern.24 Patients were given an empty
body diagram showing the human outlines from all four
perspectives (front, back, left, and right). For detailed
documentation, PDs additionally included enlarged pic-
tures of the head, hands and feet, shown from different
angles. Investigators instructed patients to mark all painful
sensations using a red pencil. Patients were free to depict
their pain sensations how they felt was most accurate,
using lines, circles, crosses, arrows, hatches, solidiﬁed
areas, etc. PDs were systematically analyzed according to
deﬁned variables, which have demonstrated their differen-
tial diagnostic utility in previous studies (eg number of
marks, length of longest mark, and axial symmetry etc.).27
Examples of variables derived from the pain drawings are:
WPI (amount of marks fulﬁlling WPI criteria) and indica-
tor B (multilocular bilateral pain-patterns) fulﬁlled, when
there were ≥3 pairs of axial-symmetric marks. Different
pain distribution pattern categories have been documented
in previous literature, upon which predominantly localized
pain syndromes (non-whole-body variants) are differen-
tiated from predominantly generalized pain syndromes
(whole-body variants) in the present study.27,46 Whole-
body pain was deﬁned as pain distribution affecting at
least 4 of 6 body segments (including the extremities,
trunk and head)
Statistical analyses
SPSS 21 (SPSS Inc., Chicago, IL, USA) was used for
statistical analyses. Normal data distribution was tested
with the Kolmogorov–Smirnoff test and if not fulﬁlled,
non-parametric statistical analyses were applied.
Descriptive statistics were used to compare patient groups
on sociodemographic data, clinical symptoms, pain his-
tory, and psychiatric comorbidity. Group comparisons for
categorical variables used Pearson’s chi-squared test or
Fisher’s exact test where appropriate. The Mann–
Whitney test or an independent sample t-test was used to
compare continuous variables. The signiﬁcance level was
set at p<0.05 (two-tailed). The Pearson product-moment
correlations coefﬁcient were used to test associations
between SSS, WPI, psychopathological distress scales
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(HADS; BSI), algometric data and baseline pain measure-
ments. Spearman’s rho correlation coefﬁcients were used
for respective non-parametric analyses. Regarding psycho-
metric data, sum or mean scores of subscales and total
scores were used respectively. To determine the discrimi-
native ability of the different binary diagnostic sets, diag-
nostic odds ratios (DOR) and correct classiﬁcation rates
were calculated.47
Results
409 patients with functional pain syndromes were
included. Table 1 shows demographic and basic pain char-
acteristics of the sample across both pain distribution sub-
groups. 169 patients (41.3%) had whole-body pain and
240 patients (58.7%) had non-whole-body pain. Patients
with non-whole-body pain had diagnoses such as chronic
cervical pain syndromes; atypical chronic limb syndromes;
functional pain associated hemi-disorders; quadrant-speci-
ﬁc pain syndromes; chronic chest, trunk, or low back pain
and chronic tension headache. Additive comorbid pain
disorders were chronic temporomandibular disorder;
chronic atypical facial pain syndrome; chronic abdominal
pain and chronic pelvic pain syndromes. 62.3–75.5% of
patients with whole-body pain had FM-like disorders, 1
patient suffered from cenesthesia, the other patients in the
whole-body pain group exhibited pain, which was best
described as “combinations of several local pain syn-
dromes”. About half of all the patients with functional
pain syndromes (196/397, 47.9%) fulﬁlled the FM criteria
when diagnosed with the 2011 criteria, of which 76
(31.9%) represented non-whole-body pain syndromes.
Whereas ABC indicators are more selective: Less than a
third of all patients with functional pain syndromes (112/
360, 31.1%) would receive the FM diagnosis.
Taking FM as a distinct phenotype with generalized
pain, we expected signiﬁcantly different clinical proﬁles
for whole-body compared to non-whole-body variants.
Table 2 shows the results of comparisons on the different
indicators. Overall, statistically signiﬁcant differences
emerged among all individual indicators (A, B & C).
Generally, the whole-body pain group displayed a signif-
icantly higher frequency of symptoms in all areas.
Indicator B (bilateral axial symmetric pain pattern) has,
as expected, the best effect size (Cohen’s d) to distin-
guish the whole-body from the non-whole-body group.
The non-whole-body pain group showed signiﬁcantly
higher HADS anxiety (p<0.001, d=0.92) and depression
(p<0.001, d=0.96) levels compared to healthy normal
controls.48 The whole-body pain group also showed sig-
niﬁcantly higher HADS anxiety (p<0.001, d=1.17) and
depression (p<0.001, d=1.07) levels compared to healthy
normal controls.48 Yet, between the subgroups, statisti-
cally signiﬁcant differences emerged in all algometric and
psychometric aspects except for the depression-scores.
Notably, concerning distress (Indicator C), both the
HADS and the BSI total scores showed statistically sig-
niﬁcant differences. With regard to indicator C, the SSS
2011 showed the largest effect for a difference based on
Cohen’s d.
Table 3 displays the correlations of the SSS 2011 with
the various measures of distress. All distress measures
correlated signiﬁcantly with the SSS 2011 with values
between r =0.3 and 0.42, indicating moderate associations.
Table 4 shows the results of the speciﬁcity, sensitivity
and DOR in identifying FM using either the FM 2011cri-
teria or the ABC indicators. The speciﬁcity of the ABC
indicators was substantially higher than that of the FM
2011 criteria, whereas the sensitivity of the ABC indica-
tors was lower than that of the FM 2011 criteria. As a
measure of overall diagnostic performance, the diagnostic
odds ratio of the ABC indicators was substantially higher
than that of the FM 2011 criteria.
Table 1 Health characteristics of 409 patients with functional pain syndromes according to their anatomical pain distribution patterns
Functional pain syndromes Non-whole-body variant Whole-body variant
Subsample size (n) 240 (58.7%) 169 (41.3%)
Age (years) 47.1 (±13.4) 48.2 (±10.6) n.s.
Sex (male) 47.5% (114/240) 40.2% (68/169) n.s.
Time since pain ﬁrst occurred (months) 88.9 (±134.0) 106.00 (±110.4) n.s.
Average pain intensity (NRS 0–10) 6.5 (±1.8) 6.78 (±2.0) n.s.
FM 2011 criteria 31.9% (76/238) 75.5% (120/159) ***
ABC indicators (for details see Tables 3 and 4) 11.7% (26/222) 62.3% (86/138) ***
Notes: Mean (± SD). ***p<0.001. t-tests and chi-square tests were implemented to test for signiﬁcant differences between groups.
Abbreviations: NRS, numerical rating scale, n.s., not signiﬁcant.
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Discussion
The proposed ABC indicators are a clinically based further
development of the 2011 FM criteria. The indicators have
been developed based on the current pathophysiological
understanding of FM as a complex generalized pain syn-
drome. “A” stands for Algesia, “B” for Bilateral, axial-
symmetric pain distribution, and “C” for Chronic distress.
We evaluated the diagnostic accuracy of the ABC
indicators compared to the FM 2011 criteria (WPI and
SSS 2011) analyzing data of 409 chronic functional pain
patients. The ABC indicators increased the speciﬁcity of
the FM diagnosis by 20% to 88.3% (compared to 68.1%
with the conventional 2011 criteria), and the DOR
increased by 90.0% from 6.56 to 12.47, indicating superior
diagnostic performance.
Crucially, our data emphasize the notion that FM repre-
sents a distinct phenotype within the spectrum of functional
pain disorders. Accordingly, patients in the whole-body
pain group showed signiﬁcantly higher pain sensitivity
(Indicator A), higher rates of bilateral axial-symmetric
pain pattern (Indicator B) and higher levels of distress
symptoms (Indicator C), compared to patients with non-
whole-body pain (Table 2). Notably, levels of anxiety dif-
fered signiﬁcantly between both groups, too (HADS and
BSI). In line with previous ﬁndings, high anxiety levels may
also be a distinctive feature of FM.49 Finally, the lowered
pain, stress, and anxiety thresholds in FM may be expres-
sions of the same underlying central hypersensitivity
mechanism.50 Notably, research has established the under-
standing of the overlap between stress and anxiety in their
underlying neurobiological processes, a ﬁnding that sup-
ports our results.51 Animal models have demonstrated, that
the anterior cingulate cortex plays a central role in the
sensitization, long-term potentiation, and emulsiﬁcation of
Table 2 Differences in FM characteristics between non-whole-body and whole-body variants
Non-whole-body pain Whole-body pain Odds ratio or Cohen’s d p-value
WPI 4.54 (±3.21) 9.23 (±4.06) 1.28 0.001
Indicator A (hyperalgesia) 48.1% 69.8% 1.91 0.009
Pain sensitivity middle ﬁnger 3.46 (±2.64) 4.41 (±2.87) 0.34 0.002
Pain sensitivity earlobe 6.91 (±2.99) 7.85 (±2.84) 0.32 0.005
Indicator B (bilateral pain) 30.0% 94.7% 41.57 0.001
Indicator C (chronic distress)
HADS total distress 18.60 (±8.93) 20.42 (±9.21) 0.20 0.049
HADS depression 9.39 (±4.96) 9.82 (±4.77) 0.09 0.390
HADS anxiety 9.21 (±4.92) 10.59 (±5.28) 0.27 0.009
BSI total 0.96 (±0.66) 1.13 (±0.67) 0.26 0.020
BSI depression 1.06 (±0.98) 1.17 (±0.97) 0.11 0.300
BSI anxiety 1.04 (±0.83) 1.30 (±0.84) 0.30 0.006
SSS 2011 6.61 (±2.49) 7.66 (±2.14) 0.45 0.001
Abbreviations: HADS, Hospital Anxiety and Depression Scale; BSI, Brief Symptom Inventory; WPI, Widespread Pain Index; SSS, Symptom Severity Scale.
Table 4 Sensitivity, speciﬁcity, correct classiﬁcation and DOR
Non-whole-body variants
(True-negative speciﬁcity)
Whole-body variants
(True-positive sensitivity)
Correct classiﬁcation rate DOR
FM 2011 criteria 68.1% 75.5% 71.0% 6.56 (CI: 4.17–10.31)
ABC indicators 88.3% 62.3% 78.3% 12.47 (CI: 7.30–21.28)
Abbreviations: CI, conﬁdence intervals; DOR, diagnostic odds ratio.
Table 3 Pearson correlations among SSS 2011 and indicator C
(distress) measures
Correlation coefﬁcient r
HADS-total distress 0.33***
HADS-depression 0.32***
HADS-anxiety 0.29***
BSI-total 0.42***
BSI-anxiety 0.36***
BSI-depression 0.32***
Note: ***p<0.001.
Abbreviations: SSS, Symptom Severity Scale; HADS, Hospital Anxiety and
Depression Scale; BSI, Brief Symptom Inventory.
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chronic pain and anxiety.52 Exposure to adverse experi-
ences may contribute to the synergetic processes of pain
and anxiety in FM.34
The correlations between SSS 2011 and psychological
distress measures (HADS, BSI) in this sample additionally
corroborates previous research demonstrating signiﬁcant
correlations of SSS 2011 with psychological distress.10
These results support retaining the SSS 2011 as an easy-
to-administer clinical screening measure of distress symp-
toms (Indicator C) within the ABC indicators.
Even if the SSS 2011 appears to be a viable instrument
for screening stress-related symptoms (Indicator C), the
conventional application of the 2011 FM criteria (WPI and
SSS 2011) to our patient sample yielded questionable
speciﬁcity: Nearly half of all patients with functional
pain syndromes were diagnosed with FM, and 2 out of 5
patients with local functional pain syndromes received an
FM diagnosis according to the 2011 criteria despite lack-
ing whole-body-pain.
In brief, “generalized pain”, the central aspect upon
which our study is methodologically founded, is repre-
sented as whole-body-pain in our sample. The proposition
to support the notion of “generalized pain” is in line with
recent revisions of the ACR FM criteria in 2016.11,12 We
emphasize this proﬁle of FM as a generalized pain syn-
drome in distinction from CRPS, hemi-body pain syn-
dromes, myofascial pain syndromes and many other
localized functional pain syndromes.10,53,54 One inclusion
can arguably be made regarding early stages of FM, ie
incomplete FM Syndromes, which may do not (yet) exhi-
bit a “whole-body” distribution of pain.55 However, we
surmise that even incomplete FM syndromes would corre-
spond to our indicators of hyperalgesia (indicator A),
bilateral axial-symmetric pain distribution (indicator B),
and chronic stress symptoms (indicator C).
A methodological limitation of the ABC indicators is
that, similar to the ACR criteria, they rely considerably on
patients’ self-report ratings. However, an important differ-
ence to the ACR criteria is that indicator A is implemented
through a clinical algometric assessment of the patient. A
necessary clinical assessment is arguably expedient for a
credible classiﬁcation and subsequent treatment of FM
patients.
As a preliminary limitation of the proposed ABC FM
indicators we need to emphasize that the present study
analyzed data of one sample of inpatients with functional
pain disorders, so we cannot yet generalize the diagnostic
accuracy to other settings and patient groups. Importantly,
the utility of the ABC indicators needs to be further
evaluated in outpatient settings and other patient groups
(eg orthopedic pain patients) as well, in order to establish
generalizability.
Conclusion
With the ABC indicators, the speciﬁcity of FM diagnosis
is substantially above that of the 2011 criteria, which tend
to “over-diagnose” FM. Additionally, while the sensitivity
is 13.2% below the 2011 criteria’s sensitivity, the overall
discriminative ability (DOR) of the proposed clinical indi-
cators is substantially higher than that of the 2011 criteria.
An eminent difference between the 2011 criteria and the
proposed ABC indicators lies in its completely different
clinical approach: ACR criteria 2011 diagnose FM by
exclusion and based on 2 linear scales of self-administered
symptoms. In contrast, the ABC indicators regard FM as a
tangible and complex clinical disease-entity with general-
ized hyperalgesia, which should be diagnosed face-to-face
by a physician in a structured clinical assessment in search
of positive clinical indicators. More importantly, the
underlying pathophysiological concept of the ABC indica-
tors allows for a suitable and viable communication of this
pain disorder to patients as well as to medical students and
health professionals due to its etiopathogenetic underpin-
ning. We hope to stimulate international discourse on the
improvement of the understanding of FM through our
proposed ABC indicators and encourage future research
to investigate their utility and validation in further clinical
settings.
In summary, we recommend the following approach
for identifying FM:
1. Clinical examination and serological or radiological
screens for the veriﬁcation/exclusion of lesion-based
or inﬂammatory comorbid components (according to
rheumatology standards).
2. Indicator A: Testing for generalized hyperalgesia by
quantifying hyper-perceptive components of pain
sensation using a standardized algometric measure.
3. Indicator B: Examining, eg with pain drawings, the
fulﬁlment of a bilateral axial-symmetric pain distri-
bution (fulﬁlled, when there are ≥3 pairs of WPI
marks).
4. Indicator C: Use of the SSS 2011 as a brief Stress
Symptom Screen with the cutoff of ≥5. Decide
whether a more detailed exploration of psychologi-
cal distress is required.
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5. If a patient exhibits all three indicators, the fulﬁl-
ment of the FM syndrome can be communicated
and explained, and care according to current guide-
lines a multimodal therapy should be recommended.
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